TIDMHIK

RNS Number : 3942L

Hikma Pharmaceuticals Plc

30 April 2020

Hikma appoints Douglas Hurt as Director

London, 30 April 2020 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) ( Hikma ) announces the appointment of Douglas Hurt as an independent non-executive director effective 1 May 2020. Over the course of 2020, Douglas will assume responsibility for chairing the Audit Committee.

'I am very pleased that Douglas will be joining Hikma's Board. He brings a wealth of experience, particularly in relation to operational and financial management, reporting, risk and leadership of audit committees.' said Said Darwazah, Executive Chairman. 'Over the course of 2020, we will undertake the transition of the Audit Committee chair to Douglas and the role of Senior Independent Director to Pat Butler .'

During his executive career, Douglas served as Finance Director of IMI plc, the global engineering group, from 2006 to 2015. Prior to this, he held a number of senior finance and general management positions at GlaxoSmithKline plc, which he joined in 1983, previously having worked at Price Waterhouse. His career has included several years working in the US as the Chief Financial Officer and significant experience in European businesses as an Operational and Regional Managing Director.

Douglas is the Senior Independent Director and Chairman of the Audit Committee at Vesuvius PLC and Countryside Properties PLC. He is a non-executive director and Chairman of the Audit Committee of the British Standards Institution. Douglas served as Senior Independent Director and Chairman of the Audit Committee of Tate & Lyle plc until July 2019.

Douglas is a Chartered Accountant and holds an MA(Hons) in Economics from Cambridge University.

-- ENDS --

Enquiries:

Hikma Pharmaceuticals PLC

Peter Speirs, Company Secretary +44 (0)20 7399 2772

Susan Ringdal, EVP Strategy and Global Affairs +44 (0)20 7399 2760

 
 
 

About Hikma

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we're a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner in the MENA region, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit www.hikma.com .

LEI: 549300BNS685UXH4JI75

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

BOAPPUGCCUPUGMB

(END) Dow Jones Newswires

April 30, 2020 02:00 ET (06:00 GMT)

Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Ott 2020 a Nov 2020 Clicca qui per i Grafici di Hikma Pharmaceuticals
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Nov 2019 a Nov 2020 Clicca qui per i Grafici di Hikma Pharmaceuticals